Last reviewed · How we verify
Paricalcitol, atorvastatin
This combination uses paricalcitol to activate vitamin D receptors for mineral metabolism regulation and atorvastatin to inhibit HMG-CoA reductase for cholesterol lowering.
This combination uses paricalcitol to activate vitamin D receptors for mineral metabolism regulation and atorvastatin to inhibit HMG-CoA reductase for cholesterol lowering. Used for Secondary hyperparathyroidism in chronic kidney disease patients with dyslipidemia.
At a glance
| Generic name | Paricalcitol, atorvastatin |
|---|---|
| Also known as | G2 |
| Sponsor | Ricardo Mouzo Mirco |
| Drug class | Vitamin D receptor activator + HMG-CoA reductase inhibitor (statin) |
| Target | Vitamin D receptor (VDR) + HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Paricalcitol is a selective vitamin D receptor activator that regulates calcium and phosphate homeostasis, particularly useful in chronic kidney disease. Atorvastatin is a statin that reduces LDL cholesterol by inhibiting hepatic cholesterol synthesis. Together, they address both mineral-bone metabolism and cardiovascular risk in patients with kidney disease.
Approved indications
- Secondary hyperparathyroidism in chronic kidney disease patients with dyslipidemia
Common side effects
- Hypercalcemia
- Hyperphosphatemia
- Muscle pain or myalgia
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paricalcitol, atorvastatin CI brief — competitive landscape report
- Paricalcitol, atorvastatin updates RSS · CI watch RSS
- Ricardo Mouzo Mirco portfolio CI